[Reflections on the novel definition and whether or not antiviral therapy for inactive HBsAg carrier state in the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)"]. [PDF]
Ren S, Zheng SJ, Chen XY.
europepmc +1 more source
[Analysis of antiviral efficacy in pediatric patients with HBeAg-negative chronic hepatitis B]. [PDF]
Guo X +8 more
europepmc +1 more source
[EVA1A overexpression improves non-alcoholic fatty liver disease in mice by regulating lipid metabolism and promoting lipophagy]. [PDF]
Xu J +8 more
europepmc +1 more source
[Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B]. [PDF]
Wang ZW +11 more
europepmc +1 more source
[Analysis of dietary composition in patients with liver cirrhosis: an observational study based on the database from the National Health and Nutrition Examination survey]. [PDF]
Chen XY +6 more
europepmc +1 more source
[Research progress in the field of liver failure with artificial livers in 2025]. [PDF]
Han T.
europepmc +1 more source
[Guidelines for the prevention and treatment of hepatitis C (2019 version)]. [PDF]
Chinese Society of Hepatology +2 more
europepmc +1 more source
[The partial cure represents an intermediate endpoint on the path to a functional cure, not an ideal endpoint]. [PDF]
Zhuang H.
europepmc +1 more source
[Advances in clinical features, diagnosis, and treatment of pre-acute-on-chronic liver failure]. [PDF]
Nie YH, Cai DC.
europepmc +1 more source

